MedTrace Logo

Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy

NCT01440673 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2011-09-26

No results posted yet for this study

Summary

* Gynecological surgery is associated with a high incidence of postoperative nausea and vomiting.
* NK1 receptor antagonists such as aprepitant appear to be highly effective for treating acute and delayed emesis, and yet understanding of the efficacy of different doses of aprepitant is limited.
* We performed a prospective, randomized, double-blinded placebo-controlled study of 123 female adults scheduled for laparoscopic hysterectomy who received 80 mg aprepitant, 125 mg aprepitant, or a placebo.

Conditions

  • Postoperative Nausea and Vomiting

Interventions

DRUG

Aprepitant

Aprepitant 80 mg, Aprepitant 125 mg

Sponsors & Collaborators

Principal Investigators

  • WOL SEON JUNG, M.D. Ph.D. · Gil Medical Center Gachon University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01440673 on ClinicalTrials.gov